Butterfly Network Stock Price, News & Analysis

Butterfly Network, Inc. (NYSE: BFLY) is a healthcare and digital health company focused on transforming medical imaging through portable, semiconductor-based ultrasound technology and ultrasound software solutions. The company is associated with the manufacturing of ultrasound and irradiation apparatus and operates in the broader medical imaging and manufacturing sector. Butterfly’s core approach centers on its proprietary Ultrasound-on-Chip™ semiconductor technology, which enables handheld, whole-body ultrasound imaging combined with cloud-connected, software-driven workflows.

According to company materials, Butterfly launched what it describes as the world’s first handheld, single-probe, whole-body ultrasound system, Butterfly iQ, in 2018. Subsequent generations, iQ+ and iQ3, followed in 2020 and 2024, reflecting ongoing development of processing power and performance based on semiconductor advances. The iQ3 has been recognized with the Best Medical Technology award at the Prix Galien USA Awards, and Butterfly’s innovations have appeared on lists such as Fierce 50, TIME’s Best Inventions and Fast Company’s World Changing Ideas, underscoring the company’s focus on digital medical imaging technology.

Business model and technology focus

Butterfly Network describes itself as a digital health and healthcare company that combines advanced hardware, intelligent software, artificial intelligence (AI), services and education to encourage adoption of affordable, accessible ultrasound imaging. Its handheld ultrasound probes are built on a semiconductor chip using a fully electronic 2D capacitive micromachined ultrasonic transducer (CMUT) array. This architecture enables software-defined beam steering and supports imaging across three dimensions without mechanical motion.

The company’s materials highlight that its handheld ultrasound probes, when paired with its Compass™ enterprise workflow software, can help hospital systems improve care workflows, reduce costs and enhance provider economics. Butterfly also offers Compass AI™, described as an AI-powered evolution of its enterprise software platform designed to reduce workflow friction and support scalable, revenue-ready point-of-care ultrasound (POCUS) programs for health systems. These software capabilities are positioned as a way to turn POCUS from underutilized, siloed tools into coordinated imaging services with visibility into usage, compliance and potential return on investment.

Products, platforms and programs

Butterfly’s product and platform portfolio, as described in its public communications, includes:

• Handheld ultrasound probes based on Ultrasound-on-Chip™ technology, including the Butterfly iQ family of devices, designed for whole-body imaging in a single handheld probe.
• Compass™ enterprise workflow software, which supports documentation, quality review and program management for POCUS across departments and devices.
• Compass AI™, an AI-powered operating system for POCUS program management, featuring tools for documentation, quality assurance and program dashboards.
• Butterfly Garden™, a developer and co-development environment referenced in company news, through which third-party developers can build applications that use Butterfly’s imaging capabilities, including planned access to a Beam Steering API and Ultrasound-on-Chip™ co-development programs.
• AI-enabled clinical tools, such as Auto B-line Counter for lung imaging and a Gestational Age AI tool integrated into the Butterfly app for use in certain Sub-Saharan African countries, supporting maternal and fetal health initiatives.

In addition to selling devices and software, Butterfly has entered into at least one co-development and licensing agreement around its semiconductor-based ultrasound technology. An 8-K filing dated November 17, 2025 describes a Co-Development and Licensing Agreement between Butterfly (through its subsidiary BFLY Operations, Inc.) and Midjourney, Inc. Under this agreement, Butterfly granted Midjourney an exclusive, non-transferable license within a specified field of use to access and use certain Ultrasound-on-Chip technology, software and backend technology, along with provisions for fees, milestone payments, revenue sharing and chip purchases. This illustrates how Butterfly’s semiconductor platform can also be licensed for use in other hardware products.

Clinical and global health applications

Butterfly highlights that clinical publications have examined its handheld ultrasound probes in combination with Compass enterprise workflow software, with reported benefits such as improved care workflows, cost reduction and enhanced provider economics for hospital systems. The company also emphasizes a cloud-based solution that supports mobility and what it describes as care "anywhere," aligning with its stated aim to help address global healthcare challenges through more accessible imaging.

Butterfly devices are described as commercially available to trained healthcare practitioners in areas including parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America. The company has communicated specific initiatives in Sub-Saharan Africa, including a Gestational Age AI tool for obstetrical point-of-care ultrasound in Malawi and Uganda, and a Gates Foundation–funded deployment of handheld probes and training across public health facilities in South Africa and Kenya. These programs are presented as part of Butterfly’s efforts to expand access to obstetric ultrasound and improve maternal and neonatal health outcomes in low-resource settings.

Enterprise software and AI capabilities

Butterfly’s enterprise software and AI capabilities are an important part of its offering. Compass AI is described as an AI-powered operating system intended for compliant, scalable, revenue-ready POCUS programs. Company materials state that it supports an encounter-based workflow tailored to POCUS rather than traditional order-based radiology workflows. Features referenced include:

• A Documentation Agent using ambient voice dictation to complete notes during exams.
• A QA Agent that uses AI to streamline image review and feedback.
• A Program Dashboard for tracking usage, compliance, credentialing and unbilled scans.
• Integration capabilities with systems such as electronic health records and imaging archives, intended to route studies into the medical record and reduce lost studies.
• Fleet visibility tools to support governance across users and devices.

In addition, Butterfly is developing and exposing imaging capabilities through software interfaces. The company has announced plans to release a Beam Steering API that will allow third-party developers in Butterfly Garden and Ultrasound-on-Chip co-development programs to access its digital 3D beam steering capabilities, such as off-axis beam tilt, to build advanced AI-enabled acquisition tools. This reflects a strategy of opening elements of its imaging platform to partners for application development.

Semiconductor and chip development

Butterfly’s technology is built on semiconductor chips that integrate ultrasound transducer arrays and control electronics. Company updates reference internal chip development milestones, such as completion of a P5.1 chip and initiation of a sixth-generation Apollo AI chip designed for edge AI capabilities and platform scalability. The company also notes that its handheld probes use a CMUT array with thousands of elements to enable software-defined beam steering and advanced imaging modes, such as Biplane™, iQ Slice™ and iQ Fan™ on its own platform.

Beyond internal use, the Midjourney co-development and licensing agreement illustrates that Butterfly’s chip technology can be licensed to third parties, with the agreement contemplating revenue sharing related to commercialization of hardware products incorporating Butterfly chips and payments tied to chip purchases. This indicates that Butterfly’s semiconductor technology can function as both an internal enabler and a licensable asset within its business model.

Capital markets and listing status

Butterfly Network’s Class A common stock trades on the New York Stock Exchange under the ticker symbol "BFLY", as stated in multiple press releases and SEC filings. An 8-K filing dated January 13, 2026 reports that the NYSE notified the company of its determination to commence proceedings to delist Butterfly’s public warrants (ticker symbol "BFLY WS") and to suspend trading in those warrants due to "abnormally low selling price" levels under NYSE rules. The filing specifies that this action concerns the warrants only and that trading in the company’s Class A common stock on the NYSE under the symbol BFLY is unaffected.

The same filing notes that each warrant was issued in connection with Butterfly’s business combination with Longview Acquisition Corp. and is exercisable for shares of Class A common stock at a specified exercise price, with an expiration date in February 2026. The company states in the filing that it does not believe the warrant delisting is related to its performance.

Investor communications and financial reporting

Butterfly Network regularly communicates with investors through press releases, conference presentations and SEC filings. Recent 8-K filings reference the announcement of quarterly financial results, preliminary revenue growth expectations for a given quarter, and participation in healthcare investor conferences. These filings typically furnish press releases that provide revenue figures, cash usage metrics, and qualitative commentary on business progress, including AI initiatives, enterprise readiness and chip development milestones.

The company also uses non-GAAP financial measures such as adjusted gross profit, adjusted gross margin, adjusted EBITDA and adjusted EPS, as described in its financial results press releases and related 8-K filings. Butterfly explains that these measures are used by management to assess operating performance and for financial planning and that reconciliations to the most directly comparable GAAP measures are provided in its financial disclosures.

Global reach and healthcare impact focus

Butterfly describes its mission as helping to democratize healthcare by making imaging more accessible and affordable. It emphasizes that its cloud-based platform and handheld devices can enable imaging in a variety of care settings, including point-of-care, ambulatory and frontline environments. Company communications highlight initiatives in global health, particularly in low- and middle-income countries where access to traditional ultrasound systems has been limited.

Examples include the deployment of handheld probes and training programs in Sub-Saharan Africa, as well as AI tools designed to support clinicians and lower-skilled healthcare workers in performing and interpreting obstetric ultrasound exams. The company notes that these efforts are intended to support earlier detection of complications and to inform care decisions in maternal and fetal health, while also generating data for research on outcomes such as maternal and neonatal mortality.

Position within the medical imaging and manufacturing sector

Within the broader manufacturing and medical imaging landscape, Butterfly Network aligns with irradiation apparatus and ultrasound device manufacturing, but differentiates itself by emphasizing semiconductor-based Ultrasound-on-Chip technology, handheld form factors and integrated AI-driven software. Rather than focusing solely on traditional cart-based ultrasound systems, Butterfly’s public materials stress portability, software-defined imaging modes and enterprise workflow tools that connect devices to hospital systems and cloud infrastructure.

For investors and observers, key aspects of Butterfly’s profile include its NYSE listing under BFLY, its focus on handheld ultrasound hardware and software platforms, its use of semiconductor and AI technologies in imaging, its licensing of chip technology to partners, and its stated goal of expanding access to ultrasound in both developed and under-resourced healthcare markets.